Dogs & Cats
Amoxicillin-Clavulanate (Clavamox) in Dogs and Cats: Indications, Stewardship, and Skin and UTI Evidence
Bottom line
- Amoxicillin-clavulanate (Clavamox) is a beta-lactam/beta-lactamase inhibitor combination active against a wide range of gram-positive, gram-negative, and anaerobic pathogens commonly isolated from skin, soft tissue, urinary tract, and dental infections in dogs and cats.
- Clavulanate extends amoxicillin's spectrum to include beta-lactamase-producing Staphylococcus, E. coli, and Pasteurella spp. — organisms commonly isolated from companion animal pyoderma and UTIs.
- For canine and feline urinary tract infections, the ISCAID 2019 guidelines recommend amoxicillin alone (not amoxicillin-clavulanate) as the preferred first empirical choice for sporadic uncomplicated cystitis, because urine amoxicillin concentrations are high enough to inhibit most susceptible organisms without clavulanate.
- US Clavamox Drops dosing is species-specific; use the current label and culture results to select dose and duration. [3]
- Antimicrobial stewardship principles strongly favor culture and sensitivity testing before selecting amoxicillin-clavulanate empirically to avoid unnecessary broad-spectrum use.
- This is a clinician-facing evidence summary. It is not a treatment protocol; confirm drug dosing, course duration, and indication against current formularies, ISCAID guidelines, and culture sensitivity results.
Clinical facts
- Drug class: Aminopenicillin (amoxicillin) combined with a beta-lactamase inhibitor (clavulanic acid); bactericidal; inhibits cell wall synthesis.
- Spectrum: Gram-positive cocci (Staphylococcus pseudintermedius, S. aureus, Streptococcus spp.); gram-negative rods including E. coli, Pasteurella spp., Proteus mirabilis; anaerobes. Does NOT have reliable activity against Pseudomonas aeruginosa, Enterococcus spp. at labeled doses, methicillin-resistant staphylococci (MRSP/MRSA), or Klebsiella in many clinical isolates.
- US labeled indications (Clavamox Drops): Dogs: susceptible skin/soft-tissue and periodontal infections. Cats: susceptible skin/soft-tissue infections and E. coli cystitis. Respiratory use is outside this US label. [3]
- Dosing: The US Clavamox Drops label gives dogs 6.25 mg/lb twice daily and cats 62.5 mg twice daily. Different dose schedules or indications require a separate extra-label prescribing decision. [3]
- Adverse effects: GI signs (vomiting, diarrhea) most common and dose-dependent; true allergic reactions (anaphylaxis) rare but possible; diarrhea may reflect microbiome disruption.
- Administration: The US label describes Clavamox as stable in gastric acid and not significantly affected by gastric or intestinal contents. Do not attribute administration advice to acid instability. [3]
What the evidence shows
ISCAID 2019 guidelines: UTI prescribing and amoxicillin-clavulanate stewardship
The 2019 International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for diagnosis and management of bacterial UTIs in dogs and cats (Weese et al., Veterinary Journal 247:8-25, 2019) are the current evidence-based standard for small animal UTI management.[1] For sporadic uncomplicated bacterial cystitis in dogs, the guidelines recommend amoxicillin (11 mg/kg PO q8h) or trimethoprim-sulfamethoxazole as preferred empirical first-line agents, with a 3–5 day treatment course. Amoxicillin-clavulanate is listed as an acceptable but not preferred initial choice — the rationale being that urine amoxicillin concentrations after standard dosing are high enough to inhibit most susceptible uropathogens, and there is little evidence that the addition of clavulanate improves outcomes for uncomplicated cystitis. The ISCAID guidelines explicitly state that evidence for the need for clavulanic acid in uncomplicated UTI is lacking. This stewardship principle is clinically important: empiric amoxicillin-clavulanate instead of amoxicillin alone unnecessarily adds a broader-spectrum inhibitor and should be reserved for cases where culture confirms beta-lactamase-producing organisms.
For repeated clinical urinary episodes, use the canine recurrent bacterial cystitis workflow to distinguish recurrence patterns and subclinical bacteriuria and investigate predisposing causes before selecting another antimicrobial.
Skin and soft tissue infections: amoxicillin-clavulanate with documented efficacy
The most cited controlled efficacy data for amoxicillin-clavulanate in companion animal skin infections come from an experimental and clinical study by Bywater et al. (Vet Rec, PMID 3887742) in which potentiated amoxicillin (amoxicillin-clavulanate) was compared to amoxicillin alone in experimentally induced staphylococcal skin infections in dogs and in clinical dermatological cases.[2] Lesions in animals treated with clavulanate-potentiated amoxicillin resolved significantly more rapidly than those treated with amoxicillin alone (P < 0.05 for both lesion diameter and inflammation score from Day 6 onward), with higher success rates particularly in cases where amoxicillin-resistant organisms were isolated. This study provides direct evidence for the clinical benefit of clavulanate potentiation in staphylococcal skin infections, where beta-lactamase production by S. pseudintermedius is common. For canine pyoderma, amoxicillin-clavulanate is an appropriate empirical choice while awaiting culture results, though MRSP resistance must be considered in refractory or recurrent cases.
Resistance trends and the case for culture-guided prescribing
Data from companion animal clinical microbiology consistently show rising resistance to amoxicillin as a single agent in canine uropathogens and skin isolates, while amoxicillin-clavulanate resistance rates remain lower — reflecting the continued beta-lactamase inhibition benefit for resistant isolates. A 10-year retrospective study (Italy, PMC12474177) found that amoxicillin resistance in canine uropathogens is the highest of any tested beta-lactam, while amoxicillin-clavulanate resistance has been significantly decreasing over recent years. This makes culture-guided selection all the more important: the choice between amoxicillin and amoxicillin-clavulanate should ideally be informed by sensitivity testing wherever practical.
How this fits clinical practice
Amoxicillin-clavulanate occupies a well-defined clinical niche: it is the appropriate beta-lactam for dogs and cats with skin, soft tissue, periodontal, or wound infections where beta-lactamase-producing organisms (S. pseudintermedius, E. coli, Pasteurella) are the likely or confirmed pathogen. For uncomplicated UTI, the ISCAID guidance is clear — start with amoxicillin alone, which achieves adequate urine concentrations for susceptible uropathogens without the stewardship cost of adding clavulanate empirically. For recurrent lower urinary tract signs, reassess culture, susceptibility, clinical response and underlying causes rather than treating recurrence itself as an indication for amoxicillin-clavulanate. The ISCAID drug table does not recommend amoxicillin-clavulanate for pyelonephritis or prostatitis; suspected tissue infection requires site-appropriate antimicrobial exposure and susceptibility interpretation. [1] Reconcile any gastrointestinal intolerance with the dosing plan and reassess the patient rather than attributing it to gastric acid instability. In cats, monitoring for GI signs is especially important given the fixed-dose tablet format (62.5 mg) and their narrower margin of tolerance for GI disruption.
Always confirm specific dose, course duration, and spectrum appropriateness against current culture-sensitivity results, ISCAID guidelines, and formulary. Antimicrobial stewardship principles mandate culture confirmation before multi-week courses in any patient.
Changelog
- 2026-07-02: First published.
For discharge localized to the prepuce, use the canine balanoposthitis workup to define the sampling and treatment question before selecting an antimicrobial.
Frequently Asked Questions
Should I use amoxicillin or amoxicillin-clavulanate for an uncomplicated UTI in a dog or cat?
For sporadic uncomplicated bacterial cystitis, the ISCAID 2019 guidelines recommend amoxicillin alone (11 mg/kg PO q8h) as the preferred first-line empirical agent, not amoxicillin-clavulanate. Urine amoxicillin concentrations after standard dosing are high enough to inhibit most susceptible uropathogens, and there is little evidence that adding clavulanate improves outcomes in uncomplicated cystitis.
What is the dose of amoxicillin-clavulanate (Clavamox) in dogs and cats?
The US Clavamox Drops label gives dogs 6.25 mg/lb twice daily and cats 62.5 mg twice daily. Confirm product, indication, culture results, and course duration before prescribing; other regimens are separate extra-label decisions. [3]
What organisms does clavulanate add coverage against compared with amoxicillin alone?
Clavulanate is a beta-lactamase inhibitor that extends amoxicillin's spectrum to include beta-lactamase-producing Staphylococcus (including S. pseudintermedius), E. coli, and Pasteurella spp. — organisms commonly isolated from companion animal pyoderma and UTIs.
Which pathogens are NOT reliably covered by amoxicillin-clavulanate?
At labeled doses it does not have reliable activity against Pseudomonas aeruginosa, Enterococcus spp., methicillin-resistant staphylococci (MRSP/MRSA), or Klebsiella in many clinical isolates. Methicillin resistance in particular must be considered in refractory or recurrent skin cases.
Is there evidence that clavulanate potentiation improves outcomes in canine skin infections?
Yes. A controlled experimental and clinical study (Bywater et al., Vet Rec 1985, PMID 3887742) found that staphylococcal skin lesions treated with clavulanate-potentiated amoxicillin resolved significantly more rapidly than those treated with amoxicillin alone (P < 0.05 for lesion diameter and inflammation score from Day 6 onward), with higher success rates especially where amoxicillin-resistant organisms were isolated.
How long should amoxicillin-clavulanate be given for a skin infection?
Use the product label and reassessment to determine duration. The US Clavamox Drops label describes 5–7 days or 48 hours after symptoms resolve for relevant skin/soft-tissue infections; deep pyoderma may require 21 days, with a maximum labeled duration of 30 days. Courses beyond the label require an independently justified extra-label plan. [3]
What are the most common adverse effects and how are they minimized?
Reassess gastrointestinal intolerance and suspected allergy promptly. The label contraindicates use in animals with a history of penicillin or cephalosporin allergy and describes the formulation as stable in gastric acid, without a significant influence of gastric or intestinal contents. [3]
Why do stewardship guidelines favor culture and sensitivity testing before choosing amoxicillin-clavulanate?
Empiric amoxicillin-clavulanate instead of amoxicillin alone unnecessarily adds a broader-spectrum inhibitor and should be reserved for cases where culture confirms beta-lactamase-producing organisms. Resistance data also support this: amoxicillin resistance in canine uropathogens is the highest of any tested beta-lactam while amoxicillin-clavulanate resistance has been decreasing, so the choice between the two agents is best informed by sensitivity testing wherever practical.
References
- Weese JS, Blondeau J, Boothe D, et al. International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. Vet J 247:8-25. (2019)
- Bywater RJ, Hewett GR, Marshall AB, West B. Efficacy of clavulanate-potentiated amoxycillin in experimental and clinical skin infections. Vet Rec 116(7):177-179. (1985)
- Zoetis Inc. Clavamox Drops (amoxicillin and clavulanate potassium): US prescribing information, NADA 055-101. DailyMed. (2024)
Voyage Dispatch · thevoyage.ai/forvets/knowledge/amoxicillin-clavulanate-dogs-cats-infections · published Jul 2, 2026 · verify dosing against the current formulary before prescribing
More clinical updates
Canine Balanoposthitis: Diagnostic Workup and Culture Interpretation
Localize canine preputial discharge, investigate structural disease, and interpret preputial cytology and culture without conflating normal flora with urinary infection.
Read →Canine Recurrent Bacterial Cystitis: Clinical Decisions
Distinguish recurrent canine cystitis from subclinical bacteriuria, investigate predisposing causes, and interpret culture and prevention evidence.
Read →Doxycycline for Tick-Borne Disease in Dogs and Cats: Ehrlichia, Anaplasma, RMSF, and Lyme
Doxycycline for companion-animal tick-borne disease: pathogen-specific regimens, current canine Lyme guidance, evidence from experimental Ehrlichia infection, and feline esophageal precautions.
Read →Canine Discospondylitis: Diagnosis and Treatment Decisions
Assess canine discospondylitis with targeted imaging and microbiology, distinguish fungal disease, and define medical versus surgical and monitoring decisions.
Read →